|Application ||WB, E|
|Calculated MW||26762 Da|
|Antigen Region||130-158 aa|
|Other Names||Acidic leucine-rich nuclear phosphoprotein 32 family member C, Phosphoprotein 32-related protein 1, Tumorigenic protein pp32r1, ANP32C, PP32R1|
|Target/Specificity||This ANP32C antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 130-158 amino acids from the Central region of human ANP32C.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||ANP32C Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Tissue Location||Expressed in activated stem cells, such as mobilized CD34+ cells and cord blood CD34+ cells, but not in resting bone marrow CD34+ cells. Expressed in a variety of neoplastic cell lines, mainly in prostatic adenocarcinoma cell lines. Not expressed in normal prostatic tissue|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Phosphoprotein 32 (PP32) is a tumor suppressor that can inhibit several types of cancers, including prostate and breast cancers. The protein encoded by this gene is one of at least two proteins that are similar in amino acid sequence to PP32 and are part of the same acidic nuclear phosphoprotein gene family. However, unlike PP32, the encoded protein is tumorigenic. The tumor suppressor function of PP32 has been localized to a 25 amino acid region that is divergent between PP32 and the protein encoded by this gene. This gene does not contain introns. [provided by RefSeq].
Matilla, A., et al. Cerebellum 4(1):7-18(2005)
Kochevar, G.J., et al. Hum. Mutat. 23(6):546-551(2004)
Fan, Z., et al. Nat. Immunol. 4(2):145-153(2003)
Kadkol, S.S., et al. Breast Cancer Res. Treat. 68(1):65-73(2001)
Kadkol, S.S., et al. Nat. Med. 5 (9), 1087 (1999) :
If you have any additional inquiries please email technical services at email@example.com.